First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

被引：0
|
作者：
Zhang, Huilai
Cheng, Ying
Yang, Haiyan
Zhang, Liling
Zou, Liqun
Guo, Ye
Cao, Junning
Huang, Huiqiang
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Lyu, Jiaoyan
Fang, Yiqian
Cohen, Aileen
Zhou, Keshu
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[5] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[6] Shanghai East Hosp, Tongji Univ, Sch Med, Shanghai, Peoples R China
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[9] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[10] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[11] BeiGene Beijing Ltd, Beijing, Peoples R China
[12] BeiGene USA Inc, San Mateo, CA USA
[13] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7557
引用
收藏
页数：1
相关论文
共 50 条
  • [41] POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Haioun, Corinne
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    McMillan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Giri, Pratyush
    Patil, Sushrut
    Ratnasingam, Sumita
    Prince, H. Miles
    Milliken, Samuel
    Meijide, Javier Briones
    Coyle, Luke
    Van der Poel, Marjolein
    Mulroney, Carolyn M.
    Farooqui, Mohammed Z. H.
    Wong, Hansen
    Desai, Rajendra
    Zugmaier, Gerhard
    Mergen, Noemi
    Cannell, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
  • [45] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
    Martin, Alejandro
    Redondo, Alba M.
    Dlouhy, Ivan
    Salar, Antonio
    Gonzalez-Barca, Eva
    Canales, Miguel
    Montes-Moreno, Santiago
    Ocio, Enrique M.
    Lopez-Guillermo, Armando
    Caballero, Dolores
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
  • [46] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
  • [47] Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.
    Abrisqueta, Pau
    Falchi, Lorenzo
    Phillips, Tycel Jovelle
    De Vos, Sven
    Nijland, Marcel
    Offner, Fritz
    Bykhovski, Irina
    Wu, Jun
    Wang, Liwei
    Rana, Ali
    Cordoba, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Won-Seog
    Kim, Tae Min
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle Limei
    Prince, H. Miles
    Oh, Sung Yong
    Lim, Francesca
    Carpio, Cecilia
    Tran-Der Tan
    Ayyappan, Sabarish
    Gutierrez, Antonio
    Li, Jingjin
    Ufkin, Melanie
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Walewski, Jan
    BLOOD, 2022, 140 : 1070 - 1071
  • [49] MYC plus relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.
    Epperla, Narendranath
    Maddocks, Kami J.
    Salhab, Mohamed
    Chavez, Julio C.
    Reddy, Nishitha M.
    Karmali, Reem
    Umyarova, Elvira
    Bachanova, Veronika
    Glenn, Martha Jane
    Xavier, Ana Carolina
    Zhou, Zheng
    Hernandez-Ilizaliturri, Francisco J.
    Barta, Stefan K.
    Lansigan, Frederick
    Mehta, Amitkumar N.
    Flowers, Christopher
    Cohen, Jonathon Brett
    Fenske, Timothy S.
    Hamadani, Mehdi
    Costa, Luciano J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James D.
    Huang, Da Wei
    Wright, George
    Simard, Jillian
    Muppidi, Jagan R.
    Thomas, Craig J.
    Ceribelli, Michele
    Tosto, Frances A.
    Yang, Yandan
    Xu, Weihong
    Davies-Hill, Theresa
    Pack, Svetlana
    Peer, Cody J.
    Arisa, Oluwatobi
    Mena, Esther
    Lindenberg, Maria L.
    Bergvall, Ethan
    Portell, Craig A.
    Farah, Rafic J.
    Lee, Seung Tae
    Pradhan, Amynah
    Morrison, Candis
    Tadese, Atekelt
    Juanitez, Anna M.
    Lu, Crystal
    Jacob, Allison P.
    Simmons, Heidi
    Figg, William D.
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2023, 142
12345